Trends in antiseizure medication prescription in Idiopathic generalized epilepsy over the last 10 years
- 29 November 2024
- journal article
- research article
- Published by Elsevier in Epilepsy & Behavior
- Vol. 163, 110158
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Valproate Use During Spermatogenesis and Risk to OffspringJAMA Network Open, 2024
- Levetiracetam as first‐line monotherapy for Idiopathic Generalized Epilepsy in womenActa Neurologica Scandinavica, 2021
- Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescentsCochrane Database of Systematic Reviews, 2019
- Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12‐month GENERAL studyEpilepsia, 2018
- Valproate in the treatment of epilepsy in girls and women of childbearing potentialEpilepsia, 2015
- Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood AutismJAMA, 2013
- Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromesEpilepsia, 2013
- Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: Analysis of two randomized, double-blind, placebo-controlled studiesEpilepsy Research, 2009
- The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trialThe Lancet, 2007
- Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsyEpilepsy Research, 2006